Induction of Tolerogenic Dendritic Cells Using Co-Culture with Human Olfactory Mucosa-Derived Mesenchymal Stem Cells

Abstract

RATIONALE: Measles vaccine is given as part of MMR vaccine series in 2 separate doses, achieving approximately 95-99% seroconversion rate. Determining sufficient clinical response to measles vaccine in at-risk population (e.g. healthcare workers) has not been established. METHODS: Retrospective chart review was performed on three Kings County Hospital Center employees identified as having negative measles titers, despite repeated vaccination with MMR. RESULTS: Three healthcare workers were identified with negative titers to measles during pre-employment laboratory analysis. All three cases had normal WBC counts/differential (mean WBC counts 6.1 K/uL), negative hepatitis panel and positive HepBs Ab titers. Two cases were female employees who each received a total of 4 MMR doses, with the last doses given on 12/2012 and 2/2014, respectively. Their MMR titers were respectively measured on 4/2015 and 8/2014, showing positive mumps and rubella IgG titers yet negative measles IgG. The third case involved a male employee who received a total of 6 doses of MMR, with the last dose given on 12/2013. His MMR titers were measured on 5/2014, similarly showing positive mumps and rubella IgG titers; however, measles IgG titer was equivocal-with negative repeat measles IgG on 6/2014. His serum CD3/CD4/CD8/B & T cell counts were normal. There was no history of immunodeficiency or recurrent infections in all three cases. CONCLUSIONS: We identified three cases of negative measles titers in otherwise healthy healthcare workers after repeated vaccination. Consensus to further evaluation of otherwise healthy individuals with negative laboratory vaccine response has not been established.

The Effect of Mesenchymal Stem Cells on the Expression of IDOand Qa2 Molecules in Dendritic Cells

“…34 In another study carried out by Hancharou et al, it was shown that human olfactory mucosa-derived MSCs (hOM-MSCs) can significantly increase the expression of both immunogenic (CD86) and tolerogenic (CD85k) markers of DCs. 37 In another study, it was shown that MSCs supernatant can down-regulate the expression of MHC-II and CD86 in DCs. Besides, the capability of treated DCs to inhibit T cell proliferation, generate Treg cells and cytokines expression in MLR were studied.…”